Try the BMI Calculator Table of contents Why the timing question matters for weekly GLP-1 medications The pharmacokinetic case for the 48-hour window One day early vs two days early: where the risk threshold sits The pattern problem: when occasional becomes habitual What most articles get wrong about "missing" vs "early" doses The permanent schedule-change protocol Clinical scenarios: when early dosing is the right call When early dosing creates actual risk The decision tree: should you take it early or wait Traveling across time zones: the special case What to do if you've already taken it early FAQ Why the timing question matters for weekly GLP-1 medications Semaglutide (sold as Ozempic, Wegovy, and available as compounded semaglutide) is dosed once weekly because its half-life is approximately 165 hours, or roughly 7 days (Lau et al., Clinical Pharmacokinetics 2015)

The AUC 0168h,sema,SS and other steady-state pharmacokinetic endpoints ( C max,sema,SS and R acc,DC,sema ) were analyzed separately by linear normal models based on log-transformed values with race (Japanese or Caucasian), dose group (0.5 mg or 1.0 mg), and race-by-dose group interaction as fixed factors
The titration schedule is similar but tops out one step earlier
This could help extend its half-life